{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T06:19:14Z","timestamp":1792822754785,"version":"4.5.0"},"reference-count":101,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.dsx.2023.102834","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T09:20:26Z","timestamp":1690449626000},"page":"102834","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":88,"title":["Semaglutide and cancer: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6865-5554","authenticated-orcid":false,"given":"Lakshmi","family":"Nagendra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2786-2028","authenticated-orcid":false,"given":"Harish","family":"BG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0249-2523","authenticated-orcid":false,"given":"Meha","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4915-8805","authenticated-orcid":false,"given":"Deep","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dsx.2023.102834_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.996179","article-title":"Gastrointestinal adverse events associated with semaglutide: a pharmacovigilance study based on FDA adverse event reporting system","volume":"10","author":"Shu","year":"2022","journal-title":"Front Public Health"},{"issue":"2","key":"10.1016\/j.dsx.2023.102834_bib2","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2337\/dc22-1148","article-title":"GLP-1 receptor agonists and the risk of thyroid cancer","volume":"46","author":"Bezin","year":"2023","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.dsx.2023.102834_bib3","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/07435800.2021.1955255","article-title":"Differential risk of cancer associated with glucagon-like peptide-1 receptor agonists: analysis of real-world databases","volume":"47","author":"Wang","year":"2022","journal-title":"Endocr Res"},{"issue":"1","key":"10.1016\/j.dsx.2023.102834_bib4","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/jcpt.13259","article-title":"Glucagon-like peptide-1 analogues and thyroid cancer: an analysis of cases reported in the European pharmacovigilance database","volume":"46","author":"Mali","year":"2021","journal-title":"J Clin Pharm Therapeut"},{"issue":"3","key":"10.1016\/j.dsx.2023.102834_bib5","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1210\/clinem\/dgaa891","article-title":"Do GLP-1 receptor agonists increase the risk of breast cancer? A systematic review and meta-analysis","volume":"106","author":"Piccoli","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.dsx.2023.102834_bib6","doi-asserted-by":"crossref","first-page":"206","DOI":"10.23736\/S2724-6507.20.03219-8","article-title":"Pancreatitis and pancreatic cancer in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials","volume":"48","author":"Nreu","year":"2023","journal-title":"Minerva Endocrinol"},{"issue":"9","key":"10.1016\/j.dsx.2023.102834_bib7","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1111\/dom.12926","article-title":"Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): data from randomized controlled trials","volume":"19","author":"Monami","year":"2017","journal-title":"Diabetes Obes Metabol"},{"issue":"3","key":"10.1016\/j.dsx.2023.102834_bib8","first-page":"1233","article-title":"A systematic literature review and network meta-analysis comparing once-weekly semaglutide with other GLP-1 receptor agonists in patients with type 2 diabetes previously receiving basal insulin","volume":"9","author":"Witkowski","year":"2018","journal-title":"Diabetes Ther Res Treat Educ Diabetes Relat Disord"},{"issue":"9","key":"10.1016\/j.dsx.2023.102834_bib9","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1111\/dom.13361","article-title":"Semaglutide for type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"20","author":"Andreadis","year":"2018","journal-title":"Diabetes Obes Metabol"},{"issue":"3","key":"10.1016\/j.dsx.2023.102834_bib10","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s12020-018-1708-z","article-title":"The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus: a systemic review and meta-analysis","volume":"62","author":"Li","year":"2018","journal-title":"Endocrine"},{"issue":"6","key":"10.1016\/j.dsx.2023.102834_bib11","first-page":"2183","article-title":"Orally administered semaglutide versus GLP-1 RAs in patients with type 2 diabetes previously receiving 1-2 oral antidiabetics: systematic review and network meta-analysis","volume":"10","author":"Nuhoho","year":"2019","journal-title":"Diabetes Ther Res Treat Educ Diabetes Relat Disord"},{"key":"10.1016\/j.dsx.2023.102834_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.108656","article-title":"Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"172","author":"Li","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"10.1016\/j.dsx.2023.102834_bib13","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1507\/endocrj.EJ21-0129","article-title":"Comprehensive analysis of the safety of semaglutide in type 2 diabetes: a meta-analysis of the SUSTAIN and PIONEER trials","volume":"68","author":"Yin","year":"2021","journal-title":"Endocr J"},{"issue":"9","key":"10.1016\/j.dsx.2023.102834_bib14","first-page":"1125","article-title":"Weekly semaglutide vs. Liraglutide efficacy profile: a network meta-analysis","volume":"9","author":"Alsugair","year":"2021","journal-title":"Healthc Basel Switz"},{"key":"10.1016\/j.dsx.2023.102834_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.695182","article-title":"Efficacy and safety of subcutaneous and oral semaglutide administration in patients with type 2 diabetes: a meta-analysis","volume":"12","author":"Zhong","year":"2021","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.dsx.2023.102834_bib16","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/dom.14612","article-title":"Once-weekly semaglutide for obesity or overweight: a systematic review and meta-analysis","volume":"24","author":"He","year":"2022","journal-title":"Diabetes Obes Metabol"},{"issue":"5","key":"10.1016\/j.dsx.2023.102834_bib17","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1210\/clinem\/dgab905","article-title":"An indirect treatment comparison of semaglutide 2.0 mg vs dulaglutide 3.0 mg and 4.5 mg using multilevel network meta-regression","volume":"107","author":"Lingvay","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.dsx.2023.102834_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2022.102539","article-title":"Impact of semaglutide on biochemical and radiologic measures of metabolic-dysfunction associated fatty liver disease across the spectrum of glycaemia: a meta-analysis","volume":"16","author":"Dutta","year":"2022","journal-title":"Diabetes Metabol Syndr"},{"issue":"3","key":"10.1016\/j.dsx.2023.102834_bib19","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1007\/s12020-021-02945-1","article-title":"Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis","volume":"75","author":"Zhong","year":"2022","journal-title":"Endocrine"},{"issue":"5","key":"10.1016\/j.dsx.2023.102834_bib20","article-title":"Comparing the efficacy and safety of obeticholic acid and semaglutide in patients with non-alcoholic fatty liver disease: a systematic review","volume":"14","author":"Ahmed","year":"2022","journal-title":"Cureus"},{"issue":"6","key":"10.1016\/j.dsx.2023.102834_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2022.102511","article-title":"Semaglutide for the treatment of type 2 Diabetes Mellitus: a systematic review and network meta-analysis of safety and efficacy outcomes","volume":"16","author":"Zaazouee","year":"2022","journal-title":"Diabetes Metabol Syndr"},{"issue":"4","key":"10.1016\/j.dsx.2023.102834_bib22","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1007\/s11096-022-01428-1","article-title":"Efficacy of subcutaneous semaglutide compared to placebo for weight loss in obese, non-diabetic adults: a systematic review & meta-analysis","volume":"44","author":"Arastu","year":"2022","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.dsx.2023.102834_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2022.100944","article-title":"The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP-1 RA comparators: a systematic review and network meta-analysis","volume":"28","author":"Alhindi","year":"2022","journal-title":"Contemp Clin Trials Commun"},{"key":"10.1016\/j.dsx.2023.102834_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.935823","article-title":"Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Gao","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.dsx.2023.102834_bib25","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.2147\/CLEP.S391819","article-title":"Efficacy and safety of liraglutide and semaglutide on weight loss in people with obesity or overweight: a systematic review","volume":"14","author":"Xie","year":"2022","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.dsx.2023.102834_bib26","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.2147\/DMSO.S392952","article-title":"Semaglutide 2.4 Mg for the management of overweight and obesity: systematic literature review and meta-analysis","volume":"15","author":"Smith","year":"2022","journal-title":"Diabetes, Metab Syndrome Obes Targets Ther"},{"issue":"2","key":"10.1016\/j.dsx.2023.102834_bib27","doi-asserted-by":"crossref","first-page":"65","DOI":"10.15605\/jafes.037.02.14","article-title":"Efficacy and safety of semaglutide for weight loss in obesity without diabetes: a systematic review and meta-analysis","volume":"37","author":"Tan","year":"2022","journal-title":"J ASEAN Fed Endocr Soc"},{"issue":"12","key":"10.1016\/j.dsx.2023.102834_bib28","article-title":"Efficacy of semaglutide in treating obesity: a systematic review of randomized controlled trials (RCTs)","volume":"14","author":"Anam","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.dsx.2023.102834_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110605","article-title":"Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"198","author":"Li","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.dsx.2023.102834_bib30","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.dsx.2023.102834_bib31","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3803\/EnM.2020.818","article-title":"Efficacy and safety of the novel dipeptidyl peptidase-4 inhibitor gemigliptin in the management of type 2 diabetes: a meta-analysis","volume":"36","author":"Dutta","year":"2021","journal-title":"Endocrinol Metab Seoul Korea"},{"issue":"1","key":"10.1016\/j.dsx.2023.102834_bib32","article-title":"Efficacy and safety of novel thiazolidinedione lobeglitazone for managing type-2 diabetes a meta-analysis","volume":"17","author":"Dutta","year":"2023","journal-title":"Diabetes Metabol Syndr"},{"key":"10.1016\/j.dsx.2023.102834_bib33","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"issue":"7650","key":"10.1016\/j.dsx.2023.102834_bib34","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.dsx.2023.102834_bib35","first-page":"1","article-title":"Publication and related biases","volume":"4","author":"Song","year":"2000","journal-title":"Health Technol Assess Winch Engl"},{"issue":"9","key":"10.1016\/j.dsx.2023.102834_bib36","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.2337\/dc19-0749","article-title":"PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes","volume":"42","author":"Aroda","year":"2019","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.dsx.2023.102834_bib37","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.2337\/dc19-0883","article-title":"Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial","volume":"42","author":"Rodbard","year":"2019","journal-title":"Diabetes Care"},{"issue":"15","key":"10.1016\/j.dsx.2023.102834_bib38","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1001\/jama.2019.2942","article-title":"Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"issue":"10192","key":"10.1016\/j.dsx.2023.102834_bib39","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","article-title":"Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial","volume":"394","author":"Pratley","year":"2019","journal-title":"Lancet Lond Engl"},{"issue":"7","key":"10.1016\/j.dsx.2023.102834_bib40","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S2213-8587(19)30192-5","article-title":"Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"10.1016\/j.dsx.2023.102834_bib41","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.dsx.2023.102834_bib42","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S2213-8587(19)30194-9","article-title":"Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial","volume":"7","author":"Pieber","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"10.1016\/j.dsx.2023.102834_bib43","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.2337\/dc19-0898","article-title":"Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial","volume":"42","author":"Zinman","year":"2019","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.dsx.2023.102834_bib44","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S2213-8587(20)30075-9","article-title":"Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2\/3a, randomised, controlled trial","volume":"8","author":"Yamada","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1016\/j.dsx.2023.102834_bib45","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S2213-8587(20)30074-7","article-title":"Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial","volume":"8","author":"Yabe","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.dsx.2023.102834_bib46","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1016\/j.dsx.2023.102834_bib47","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2213-8587(17)30092-X","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial","volume":"5","author":"Ahr\u00e9n","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.dsx.2023.102834_bib48","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2337\/dc17-0417","article-title":"Efficacy and safety of once-weekly semaglutide versus exenatide er in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial","volume":"41","author":"Ahmann","year":"2018","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.dsx.2023.102834_bib49","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-8587(17)30085-2","volume":"5","author":"Aroda","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.dsx.2023.102834_bib50","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1210\/jc.2018-00070","article-title":"Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial","volume":"103","author":"Rodbard","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"19","key":"10.1016\/j.dsx.2023.102834_bib51","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.dsx.2023.102834_bib52","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"10.1016\/j.dsx.2023.102834_bib53","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S2213-8587(19)30311-0","article-title":"Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial","volume":"7","author":"Lingvay","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1016\/j.dsx.2023.102834_bib54","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S2213-8587(19)30066-X","article-title":"Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial","volume":"7","author":"Zinman","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.dsx.2023.102834_bib55","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.diabet.2019.101117","article-title":"Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)","volume":"46","author":"Capehorn","year":"2020","journal-title":"Diabetes Metab"},{"issue":"9","key":"10.1016\/j.dsx.2023.102834_bib56","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1111\/dom.14765","article-title":"Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): a randomized, open-label, multinational, phase 3b trial","volume":"24","author":"Kellerer","year":"2022","journal-title":"Diabetes Obes Metabol"},{"issue":"9","key":"10.1016\/j.dsx.2023.102834_bib57","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S2213-8587(21)00174-1","article-title":"Efficacy and safety of once-weekly semaglutide 2\u00b70 mg versus 1\u00b70 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial","volume":"9","author":"Fr\u00edas","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"10.1016\/j.dsx.2023.102834_bib58","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-Weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"10278","key":"10.1016\/j.dsx.2023.102834_bib59","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet Lond Engl"},{"issue":"14","key":"10.1016\/j.dsx.2023.102834_bib60","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.dsx.2023.102834_bib61","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.dsx.2023.102834_bib62","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.dsx.2023.102834_bib63","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S2213-8587(22)00008-0","article-title":"Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial","volume":"10","author":"Kadowaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"24","key":"10.1016\/j.dsx.2023.102834_bib64","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","article-title":"Once-Weekly semaglutide in adolescents with obesity","volume":"387","author":"Weghuber","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.dsx.2023.102834_bib65","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.dsx.2023.102834_bib66","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/dom.14232","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: a 30-week, double-blind, phase 3a, randomized trial","volume":"23","author":"Ji","year":"2021","journal-title":"Diabetes Obes Metabol"},{"issue":"5","key":"10.1016\/j.dsx.2023.102834_bib67","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1111\/dom.13218","article-title":"Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: a randomized trial","volume":"20","author":"Kaku","year":"2018","journal-title":"Diabetes Obes Metabol"},{"issue":"6","key":"10.1016\/j.dsx.2023.102834_bib68","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.dsx.2023.102834_bib69","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"issue":"10148","key":"10.1016\/j.dsx.2023.102834_bib70","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"O'Neil","year":"2018","journal-title":"Lancet Lond Engl"},{"issue":"2","key":"10.1016\/j.dsx.2023.102834_bib71","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/dom.13082","article-title":"Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes","volume":"20","author":"Seino","year":"2018","journal-title":"Diabetes Obes Metabol"},{"issue":"6","key":"10.1016\/j.dsx.2023.102834_bib72","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.dsx.2023.102834_bib73","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1111\/dom.15020","article-title":"Once-weekly semaglutide use in patients with type 2 diabetes: real-world data from the SURE Italy observational study","volume":"25","author":"Napoli","year":"2023","journal-title":"Diabetes Obes Metabol"},{"issue":"7","key":"10.1016\/j.dsx.2023.102834_bib74","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1111\/dom.15045","article-title":"Once-weekly semaglutide use in patients with type 2 diabetes: results from the SURE France multicentre, prospective, observational study","volume":"25","author":"Mohammedi","year":"2023","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.dsx.2023.102834_bib75","article-title":"Real world effectiveness of subcutaneous semaglutide in type 2 diabetes: a retrospective, cohort study (Sema-MiDiab01)","volume":"13","author":"Berra","year":"2022","journal-title":"Front Endocrinol"},{"issue":"4","key":"10.1016\/j.dsx.2023.102834_bib76","first-page":"205","article-title":"Real-world use of once-weekly semaglutide in type 2 diabetes: results from SemaglUtide real-world evidence (SURE) Germany","volume":"131","author":"Menzen","year":"2023","journal-title":"Exp Clin Endocrinol Diabetes Off J Ger Soc Endocrinol Ger Diabetes Assoc"},{"issue":"3","key":"10.1016\/j.dsx.2023.102834_bib77","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s12325-022-02385-x","article-title":"Once-Weekly semaglutide use in type 2 diabetes: real-world data from the SURE Netherlands observational study","volume":"40","author":"Wolffenbuttel","year":"2023","journal-title":"Adv Ther"},{"issue":"3","key":"10.1016\/j.dsx.2023.102834_bib78","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000527919","article-title":"Efficacy and safety of semaglutide, a glucagon-like peptide-1 receptor agonist in real-life: a case series of patients in maintenance incremental hemodialysis","volume":"12","author":"De la Flor","year":"2022","journal-title":"Case Rep Nephrol Dial"},{"issue":"21","key":"10.1016\/j.dsx.2023.102834_bib79","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.3390\/nu14214673","article-title":"Once-Weekly subcutaneous semaglutide improves fatty liver disease in patients with type 2 diabetes: a 52-week prospective real-life study","volume":"14","author":"Volpe","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.dsx.2023.102834_bib80","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.995646","article-title":"Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain","volume":"13","author":"Garcia de Lucas","year":"2022","journal-title":"Front Endocrinol"},{"issue":"17","key":"10.1016\/j.dsx.2023.102834_bib81","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.3390\/jcm11174938","article-title":"Once-Weekly semaglutide use in patients with type 2 diabetes: results from the SURE Spain multicentre, prospective, observational study","volume":"11","author":"Bellido","year":"2022","journal-title":"J Clin Med"},{"issue":"10","key":"10.1016\/j.dsx.2023.102834_bib82","first-page":"1779","article-title":"Effectiveness and safety of once-weekly semaglutide in Japanese patients with type 2 diabetes in treatment intensification: a retrospective observational single-center study","volume":"13","author":"Yamada","year":"2022","journal-title":"Diabetes Ther Res Treat Educ Diabetes Relat Disord"},{"key":"10.1016\/j.dsx.2023.102834_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.rce.2022.03.009","article-title":"Real-life effects of adding weekly subcutaneous semaglutide to insulin for the treatment of type 2 diabetes mellitus","author":"Ares-Blanco","year":"2022","journal-title":"Rev Clin Esp"},{"issue":"8","key":"10.1016\/j.dsx.2023.102834_bib84","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1007\/s40618-022-01799-2","article-title":"Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients","volume":"45","author":"Marzullo","year":"2022","journal-title":"J Endocrinol Invest"},{"issue":"11","key":"10.1016\/j.dsx.2023.102834_bib85","first-page":"2891","article-title":"Real-world use of once-weekly semaglutide in type 2 diabetes: results from the SURE UK multicentre, prospective, observational study","volume":"12","author":"Holmes","year":"2021","journal-title":"Diabetes Ther Res Treat Educ Diabetes Relat Disord"},{"issue":"10","key":"10.1016\/j.dsx.2023.102834_bib86","doi-asserted-by":"crossref","DOI":"10.1111\/dme.14655","article-title":"Once-weekly subcutaneous semaglutide treatment for persons with type 2 diabetes: real-world data from a diabetes out-patient clinic","volume":"38","author":"Hansen","year":"2021","journal-title":"Diabet Med J Br Diabet Assoc"},{"issue":"5","key":"10.1016\/j.dsx.2023.102834_bib87","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.pcd.2021.06.008","article-title":"Real-world use of once-weekly semaglutide in patients with type 2 diabetes: results from the SURE Denmark\/Sweden multicentre, prospective, observational study","volume":"15","author":"Rajamand Ekberg","year":"2021","journal-title":"Prim Care Diabetes"},{"issue":"2","key":"10.1016\/j.dsx.2023.102834_bib88","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2021-002619","article-title":"Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups","volume":"10","author":"Yale","year":"2022","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"5","key":"10.1016\/j.dsx.2023.102834_bib89","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.clinthera.2021.03.003","article-title":"Real-world effectiveness of once-weekly semaglutide from a US commercially insured and medicare advantage population","volume":"43","author":"Visaria","year":"2021","journal-title":"Clin Therapeut"},{"issue":"2","key":"10.1016\/j.dsx.2023.102834_bib90","first-page":"527","article-title":"Real-world effectiveness analysis of switching from liraglutide or dulaglutide to semaglutide in patients with type 2 diabetes mellitus: the retrospective REALISE-DM study","volume":"12","author":"Jain","year":"2021","journal-title":"Diabetes Ther Res Treat Educ Diabetes Relat Disord"},{"issue":"1","key":"10.1016\/j.dsx.2023.102834_bib91","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/dom.14195","article-title":"Adherence and persistence among patients with type 2 diabetes initiating dulaglutide compared with semaglutide and exenatide BCise: 6-month follow-up from US real-world data","volume":"23","author":"Mody","year":"2021","journal-title":"Diabetes Obes Metabol"},{"issue":"11","key":"10.1016\/j.dsx.2023.102834_bib92","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1111\/dom.14117","article-title":"Semaglutide once weekly in people with type 2 diabetes: real-world analysis of the Canadian LMC diabetes registry (SPARE study)","volume":"22","author":"Brown","year":"2020","journal-title":"Diabetes Obes Metabol"},{"issue":"4","key":"10.1016\/j.dsx.2023.102834_bib93","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.3390\/ijms22041680","article-title":"Diabetes, antidiabetic medications and cancer risk in type 2 diabetes: focus on SGLT-2 inhibitors","volume":"22","author":"D\u0105browski","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.dsx.2023.102834_bib94","doi-asserted-by":"crossref","first-page":"828","DOI":"10.3390\/jpm11090828","article-title":"The risk of bladder cancer in type 2 diabetes mellitus with combination therapy of SGLT-2 inhibitors and pioglitazone","volume":"11","author":"Li","year":"2021","journal-title":"J Personalized Med"},{"issue":"3","key":"10.1016\/j.dsx.2023.102834_bib95","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.145","article-title":"The association of sodium-glucose cotransporter 2 inhibitors with cancer: an overview of quantitative systematic reviews","volume":"3","author":"Pelletier","year":"2020","journal-title":"Endocrinol Diabetes Metab"},{"issue":"8","key":"10.1016\/j.dsx.2023.102834_bib96","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1111\/dom.13745","article-title":"Sodium-glucose co-transporter-2 (SGLT-2) inhibitors and cancer: a meta-analysis of randomized controlled trials","volume":"21","author":"Dicembrini","year":"2019","journal-title":"Diabetes Obes Metabol"},{"issue":"10","key":"10.1016\/j.dsx.2023.102834_bib97","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1097\/MPA.0000000000002197","article-title":"Glucagon-like peptide 1-based therapies and risk of pancreatic cancer in patients with diabetes and obesity","volume":"51","author":"Krishnan","year":"2022","journal-title":"Pancreas"},{"issue":"2","key":"10.1016\/j.dsx.2023.102834_bib98","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/pds.5550","article-title":"A systematic review and meta-analysis of observational studies of the association between the use of incretin-based therapies and the risk of pancreatic cancer","volume":"32","author":"Hidayat","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"10.1016\/j.dsx.2023.102834_bib99","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2337\/dci22-0052","article-title":"Putting GLP-1 RAs and thyroid cancer in context: additional evidence and remaining doubts","volume":"46","author":"Thompson","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2023.102834_bib100","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.2147\/DMSO.S305496","article-title":"Risk of thyroid cancer associated with use of liraglutide and other antidiabetic drugs in a US commercially insured population","volume":"14","author":"Funch","year":"2021","journal-title":"Diabetes, Metab Syndrome Obes Targets Ther"},{"key":"10.1016\/j.dsx.2023.102834_bib101","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/924168","article-title":"A review on the association between glucagon-like peptide-1 receptor agonists and thyroid cancer","volume":"2012","author":"Chiu","year":"2012","journal-title":"Exp Diabetes Res"}],"container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402123001303?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402123001303?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:23:27Z","timestamp":1761729807000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402123001303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":101,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1871402123001303"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2023.102834","relation":{},"ISSN":["1871-4021"],"issn-type":[{"value":"1871-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Semaglutide and cancer: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2023.102834","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Research Trust of DiabetesIndia (DiabetesIndia) and National Diabetes Obesity and Cholesterol Foundation (N-DOC). Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102834"}}